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FMD – Essential info 
• Viral disease of “Cloven hoofed animals” 
 
 
 
• Picornavirus - 7 serotypes 
• High morbidity - low mortality 
 
FMD direct impact 
• Highly infectious 
– R0 2 - 70 (depending on the setting)      
– High attack rate in outbreaks (>70%) 
– Repeated outbreaks affecting many animals 
– Rapid spread 
– 3-5 day incubation & pre-infectious period 
– UK 2001 - >56 farms infected before disease detected  
• Reduced productivity 
– Especially commercial dairy 
– Prevents use of high productivity breeds 
– Reduced traction (beasts of burden) 
FMD indirect impact 
• Trade restrictions 
– FMD free countries block imports from FMD 
affected countries/zones 
• Disastrous for exporting countries 
– Cost of control 
• Movement/trade restrictions 
– May discourage reporting 
• Vaccination (only measure in most endemic countries) 
• Culling & compensation 
» Impact on other industries (tourism) 
 
Figure 1: Upper panel – May 2015 OIE global FMD 
status showing outbreaks in FMD-free 
countries/zones that occurred between Jan 2005 
and Jan 2016 - map adapted from OIE members 
FMD status map extracted 4th April 2016 from 
http://www.oie.int/en/animal-health-in-the-
world/official-disease-status/fmd/en-fmd-carte/. 
 
Middle panel - global burden of FMD in cattle in 
2008 (burden in sheep and goats has a similar 
distribution). Prevalence index based on 
estimates of incidence, population distribution 
and other risk factors, adapted from (Sumption 
et al., 2008). Note progress in South America 
since 2008 [compare with upper panel]. 
 
Lower panel - density of poor livestock keepers, 
updated 2012 (Thornton et al., 2002). Central 
America, zones in Kazakhstan and Southern 
Africa, parts of both South East Asia and South 
America are among the few places where FMD is 
not present in poor livestock keeper populations. 
FMD conjectured status and serotypes 
Paton et al. 2009 
Control measures 
a) Movement restrictions 
a) Close markets 
b) Between farms, zones, … 
c) Wildlife 
b) Other biosecurity 
a) Fomite control 
b) Vector control (people, insects, objects,….) 
c) Cleaning and disinfection of affected premises 
d) Culling (affected, dangerous contacts,…) 
e) Vaccination 
a) Mass vaccination 
b) Targeted vaccination 
a) Ring/reactive vaccination 
b) Zonal (Cordon Sanitaire) 
c) Specific risk group 
c) Private verses public funded vaccination 
 
• Use of control zones – see Botswana, South Africa 
 
• Which measures reduce exposure and which reduce susceptibility? 
Lancisi 1711 
http://post.queensu.ca/~forsdyke/rindpst0.htm 
FMD vaccines 
• Inactivated 
• Serotype specific protection 
– Variation in protection between strains within serotype 
– Multivalent vaccines used 
• Short duration (<6 months?)  
– from serology & challenge studies 
• Repeated vaccination throughout life 
• Two dose 30 days apart primary course 
– Important but often not given 
• Poor stability (3-8ºC) 
• Sometimes can distinguish infected from 
vaccinated+uninfected – NSP purified vaccines 
• Non-Structural Protein (NSP) serology 
 
Approximate global FMD vaccination 
Used to eradicate FMD from Europe (1991-2) 
 
 
Region Million doses/Year Comments 
China 1.6 billion doses 5 government producers 
South America 500 Brazil: 350 million doses 
Asia (excluding China) 200 India: 150 million doses 
Middle East 20 
European region 20 Mainly Turkey 
Africa 15 Hamond, 2010 
What are the advantages and disadvantages 
of using vaccination to control FMD? 
Vaccination 
• Vaccination based control: 
– Advantages 
• May not need to cull 
• Protection even if cannot apply other control measures to reduce virus exposure 
• Sounds simple! 
– Disadvantages 
• Short duration of immunity 
• Limited spectrum of protection 
• Population turnover – young are highly susceptible 
• Cost – who pays? 
• Ongoing protection needed 
• False sense of security-affects risk behaviour 
• Vaccine quality/vaccine match 
• Coverage – herd immunity needed 
• Probably need biosecurity as well 
• Incentives for continued vaccination when not working 
• Needs thorough evaluation 
• Logistics of vaccinating million of livestock 
• Strain on veterinary services 
• Top down approach – inconsiderate of field situation needs of farmers 
• Mask infection/transmission – carriers 
• Affects ability to prove disease freedom 
• Affects trading restrictions if free but vaccinate 
 
 
 
Current evaluation methods 
• Vaccine protection: 
– Challenge studies – PD50, PPG 
• Small numbers 
• Unnatural challenge 
– In vitro serological vaccine matching studies 
• r-values, Expected percentage protection 
• Do not actually assess if animals are protected 
– Sero-surveys 
• To assess post-vaccinal antibody response 
• Population immunity (Structural Protein [SP] titre) 
– With antibody titre as a correlate of protection 
– Cannot tell if sero-positive from natural infection or vaccination 
» High sero-prevalence =good or bad vaccination programme 
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r-value matching test 
Current evaluation methods 
• Sero-prevalence surveys as indicator of burden 
• Vaccine protection: 
– Serological correlate of protection 
• Limited protection against different serotypes/strains 
• New strains appear frequently 
• Vaccine coverage: 
– Distributed method 
• Number of doses distributed/Estimated population size 
• Vaccination programme impact 
– ? 
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Protection in the field may vary 
Cold chain 
Shelf life 
Batch variability 
Variable animal response 
Field protection: 
protection that counts 
Match with field virus 
Time since last vaccinated 
Number of doses in lifetime 
Level/duration of virus exposure 
FMD vaccine evaluation 
Challenge 
studies 
in vitro 
matching 
assays 
Post-
vaccination 
serology 
Vaccine 
effectiveness 
Other… 
1. Are vaccinated animals protected? 
 
 
2. Are the animals being vaccinated (adequately)? 
  
Key questions for a vaccination programme: 
 
 Vaccine effectiveness 
 
 
 Vaccine coverage 
Vaccine coverage… questions 
• What levels of coverage are achieved? 
– Are there important groups of under-vaccinated 
stock? 
• How does coverage vary over the annual 
production cycle? 
– Considering population turnover 
– How does this relate to key epidemiological 
events? 
• Spring turn out to grazing 
• Times of mass trading & livestock movements 
 
Reduction in risk in similarly exposed vaccinated 
compared to unvaccinated animals in the field 
 
 
Vaccine effectiveness 
  
FMD vaccine studies in Turkish cattle 
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FMD vaccine protection: 
- Requires several doses (≥3PD50) 
- Declines with time since vaccination 
Mass vaccination 
 Mass vaccination 
Population immunity ≈ Population vaccination history 
 [No. of doses, time since last dose] 
Population vaccine history ≈ Population age structure 
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Mass vaccination twice a year: 
  Population age-sex-vaccination distribution 
 
 
Beef suckler cattle: 
Percentage of population 
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Mass vaccination twice a year: 
  Population age-sex-vaccination distribution 
 
 
Beef fattener cattle: 
9-10 doses 
7-8 doses 
5-6 doses 
Age Females 
4-5 years 
 
3-4 years 
 
2-3 years 
 
1-2 years 
 
0-1 years 
Males 
Percentage of population 
Females 
Different production system = different age structure = different population immunity 
25 
Population vaccine history & immunity varies by region 
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Structure changes with births & deaths 
over the annual production cycle  
New births = New unvaccinated animals 
Population immunity is constantly changing with 
population turnover & declining antibodies 
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Post-vaccination immunity also declines with time 
Vaccinated 
Spring+Autumn 
2012 
Vaccinated 
Autumn 2011+ 
Spring+Autumn 
2012 
Protection 
threshold once twice 3 times 
2.3 
2.4 
2 
0 
Log10 (SP titre) 
Autumn mass 
vaccination 
Vaccinated 
 Autumn 2012 
depending vaccine history 
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Population coverage model 
• Describe population immunity over the production 
cycle with 2012 Turkish mass vaccination policy 
• Simulated the Turkish cattle population for each 
province 
• Age-structure by day and month of birth 
• Using data from national random surveys for each province and census data 
 
 
• Dynamic population model representing the changing age 
structure for each province over the annual production cycle 
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Küçükkalecik 
Işıklar 
1 2 
3 4 
3 
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Percentage never vaccinated 6 months after mass vaccination 
 – if eligible cattle always vaccinated 
Unvaccinated = Cattle too young at prior vaccination 
+ 
New births since prior vaccination 
median values reported 
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Vaccinated ≥3 times  = Adult cattle 
Percentage vaccinated ≥3 times in lifetime 
 – if eligible cattle always vaccinated 
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Field studies and routine data found 40–99.9% vaccinated 
But not all eligible cattle will be vaccinated 
Results: 
 
• Six months after the last round of vaccination almost 
half of the cattle aged ≤24 months remain unvaccinated 
Betapert distribution (minimum=40%, maximum=100%, most likely=80%)  
• Only 50% of all cattle would have been vaccinated more 
than once with the last dose received ≤6 months ago 
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• Using regression models fitted to data from 
extensive post-vaccination sero-monitoring study 
[n=647] 
• Predict immunity for simulated population 
 
LPBE SP titre = Time since vaccination + No. of times vaccinated 
From coverage to immunity 
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Population immunity predictions 
Primary course Autumn mass 
vaccination 
Two-dose primary course: 
Increases proportion of 
 6-12 month cattle above 
threshold by 25-40% 
 
Log10 (SP titre) ≥2:    32% [25%-40%] 
Log10 (SP titre) ≥ 2: 27% [20%-35%] 
Log10 (SP titre) ≥ 2: 30% [24%-38%] 
Log10(SP titre) 
Threshold titre is useful but 
Titre ≈ Protection 
Antigenic similarity of: 
1) Vaccine – 2) Test – 3) Field virus 
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District coverage and population immunity 
Modelled proportion vaccinated in a district at autumn vaccination against the percentage 
of cattle with a serotype O SP titre ≥1:102 in mid February 
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Sustained antibodies after single dose 
From: Selman P, Chénard G, Dekker A (2006) Cedivac-FMD; Duration of Immunity in 
cattle, sheep and pigs. Open session of the EuFMD, Paphos, Cyprus, 17-19 October 2006  
Immunity reflects coverage 
Fewer problems  
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• Major immunity gaps despite biannual mass vaccination 
 
• Improved vaccine required 
• ≥6PD50 vaccine now routine in Turkey 
• Two-dose primary course used in certain areas 
 
• Immunity gaps will still exist 
• Each round of vaccination may exclude a quarter of all cattle 
• Often unavoidable 
 
• Improved biosecurity measures required 
• Avoid over reliance on vaccine protection 
 
Conclusions: Mass vaccination in Turkey 2012 
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What are they? 
Possible reasons for failures in FMD vaccination 
programme? 
 
Vaccine programme evaluation 
Potent 
vaccine 
Potent 
vaccine 
Vaccine 
coverage 
Field 
Protection   
 
 
Pre-field 
application 
In the field 
Why is FMD control so challenging? 
• Highly infectious with rapid transmission 
• Multispecies including wildlife 
• Multiple serotypes with variation within serotypes 
• Some farmers/regions lack motivation to control FMD  
• Vaccines: 
– Short lived protection against limited range of strains 
– Expensive & unstable (cold-chain required) 
• Subclinical infections 
• Livestock population turnover & movements 
• Cost/impact of control measures 
 
Conventional inactivated FMD vaccines 
• Adaptation of wild type virus to cell culture 
• Virulent virus grown on BHK cells 
• Inactivated (BEI) 
• Non-structural proteins removed 
• Adjuvanted with alum or oil emulsion 
• Stored frozen for stockpiling and formulated 
later 
Virus structure 
Genome 
Capsid 
- Intact viral capsids key for immune response 
- Inactivated FMD vaccine is made from whole 
virus particles and contains viral capsids but 
capsids degrade with time and the vaccine 
becomes less effective 
Novel FMD vaccines 
- Recombinant Adenovirus vectored capsids 
- Baculovirus produced stabilised capsids 
- Chimeric vaccine virus with improved culture 
adaptation and changeable cassette for 
antigenicity & DIVA 
- Synthetic peptides (vaccine containing one or 
more chemically produced antigenic proteins)
  
Adeno virus vector vaccine 
- Recombinant human adenovirus contains 
genetic code for FMDV capsids. 
- Adenovirus cannot replicate but infected cells 
will produce FMDV capsids leading to FMD 
immunity 
- No need to handle live FMD virus in production 
Baculovirus 
- Recombinant baculovirus (insect virus) 
- Contains FMDV capsid code in genome 
- Insect cell culture infected with virus produced 
empty viral capsids 
- Mutation introduced to increase capsid stability 
- These are formulated as a vaccine 
 
Chimeric vaccine virus 
- Mutant virus made by joining sections of genomes 
from different viruses 
- Use virus with good vaccine production properties 
- Replace structural protein antigen section with 
code from virus that you wish to protect against 
- Delete code coding for protein not needed in 
vaccine to differentiate vaccinated and infected 
animals 
- Produce mutant virus in cell culture 
- Use to produce inactivated vaccine in normal way 
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